JP2017500017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017500017A5 JP2017500017A5 JP2016532136A JP2016532136A JP2017500017A5 JP 2017500017 A5 JP2017500017 A5 JP 2017500017A5 JP 2016532136 A JP2016532136 A JP 2016532136A JP 2016532136 A JP2016532136 A JP 2016532136A JP 2017500017 A5 JP2017500017 A5 JP 2017500017A5
- Authority
- JP
- Japan
- Prior art keywords
- culture
- cells
- liters
- item
- viable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims description 93
- 210000004027 cell Anatomy 0.000 claims description 67
- 230000001186 cumulative effect Effects 0.000 claims description 28
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 229910052742 iron Inorganic materials 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 claims description 11
- 238000010899 nucleation Methods 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 9
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 8
- 229910052802 copper Inorganic materials 0.000 claims description 8
- 239000010949 copper Substances 0.000 claims description 8
- 230000010412 perfusion Effects 0.000 claims description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 7
- 239000002699 waste material Substances 0.000 claims description 7
- 239000011701 zinc Substances 0.000 claims description 7
- 229910052725 zinc Inorganic materials 0.000 claims description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 5
- 108010050904 Interferons Proteins 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 229940079322 interferon Drugs 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 235000015097 nutrients Nutrition 0.000 claims description 4
- 102100023961 ADP-ribosylation factor-like protein 2-binding protein Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 108010008165 Etanercept Proteins 0.000 claims description 2
- 101000757692 Homo sapiens ADP-ribosylation factor-like protein 2-binding protein Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000934823 Homo sapiens Barttin Proteins 0.000 claims description 2
- 108010005716 Interferon beta-1a Proteins 0.000 claims description 2
- 229960002964 adalimumab Drugs 0.000 claims description 2
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 2
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 2
- 229940003504 avonex Drugs 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 229960002806 daclizumab Drugs 0.000 claims description 2
- 229960000403 etanercept Drugs 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 229960000598 infliximab Drugs 0.000 claims description 2
- 229950005751 ocrelizumab Drugs 0.000 claims description 2
- 239000012716 precipitator Substances 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- 210000003501 vero cell Anatomy 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361919629P | 2013-12-20 | 2013-12-20 | |
| US61/919,629 | 2013-12-20 | ||
| PCT/US2014/071701 WO2015095809A1 (en) | 2013-12-20 | 2014-12-19 | Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020000268A Division JP2020054388A (ja) | 2013-12-20 | 2020-01-06 | 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017500017A JP2017500017A (ja) | 2017-01-05 |
| JP2017500017A5 true JP2017500017A5 (enExample) | 2018-02-08 |
Family
ID=52347449
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016532136A Withdrawn JP2017500017A (ja) | 2013-12-20 | 2014-12-19 | 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 |
| JP2020000268A Withdrawn JP2020054388A (ja) | 2013-12-20 | 2020-01-06 | 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 |
| JP2022197095A Pending JP2023022317A (ja) | 2013-12-20 | 2022-12-09 | 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020000268A Withdrawn JP2020054388A (ja) | 2013-12-20 | 2020-01-06 | 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 |
| JP2022197095A Pending JP2023022317A (ja) | 2013-12-20 | 2022-12-09 | 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20160289633A1 (enExample) |
| EP (1) | EP3083933A1 (enExample) |
| JP (3) | JP2017500017A (enExample) |
| WO (1) | WO2015095809A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160289633A1 (en) | 2013-12-20 | 2016-10-06 | Biogen Ma Inc. | Use of Perfusion Seed Cultures to Improve Biopharmaceutical Fed-Batch Production Capacity and Product Quality |
| TWI743024B (zh) | 2014-06-06 | 2021-10-21 | 美商健臻公司 | 灌注培養方法及其用途 |
| TWI776235B (zh) | 2014-06-09 | 2022-09-01 | 美商健臻公司 | 種子罐培養法(seed train processes)及其用途 |
| CA3000926A1 (en) * | 2015-11-02 | 2017-05-11 | Ares Trading S.A. | Methods for modulating production profiles of recombinant proteins in perfusion mode |
| KR20240173213A (ko) | 2016-01-26 | 2024-12-10 | 베링거 인겔하임 인터내셔날 게엠베하 | 연결된 관류 대 연속-유동식 교반-탱크 반응기 세포 배양 시스템 |
| CN115044471B (zh) | 2016-08-27 | 2025-05-27 | 三维生物科技有限公司 | 生物反应器 |
| WO2019055796A1 (en) * | 2017-09-15 | 2019-03-21 | Bristol-Myers Squibb Company | ONLINE BIOMASS CAPACITY MONITORING DURING LARGE SCALE PRODUCTION OF POLYPEPTIDES OF INTEREST |
| JP7323512B2 (ja) | 2017-10-06 | 2023-08-08 | ロンザ リミテッド | ラマン分光法を使用する細胞培養の自動制御 |
| EP4039786A1 (en) | 2017-10-16 | 2022-08-10 | Regeneron Pharmaceuticals, Inc. | Perfusion bioreactor and related methods of use |
| US20200323958A1 (en) * | 2017-11-13 | 2020-10-15 | Amgen Inc. | Methods for producing protein products |
| IL321479A (en) * | 2017-12-11 | 2025-08-01 | Amgen Inc | Lengthy manufacturing process for bispecific antibody products |
| CN110241012B (zh) * | 2018-03-09 | 2022-11-01 | 嘉和生物药业有限公司 | 一种生物大分子上游分阶段截留的生产方法、生产模块及在生产中的应用 |
| EP3787771A1 (en) * | 2018-04-29 | 2021-03-10 | REGENXBIO Inc. | Scalable clarification process for recombinant aav production |
| US12071607B2 (en) | 2018-06-01 | 2024-08-27 | Lonza Ltd. | Midscale model for organic growth and phasing |
| WO2020086408A1 (en) | 2018-10-26 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A high-yield perfusion-based transient gene expression bioprocess |
| US20210403971A1 (en) * | 2018-11-02 | 2021-12-30 | Kyowa Kirin Co., Ltd. | Method for preparing liquid medium |
| WO2020154607A1 (en) * | 2019-01-25 | 2020-07-30 | Biogen Ma Inc. | Seed culture process for aav production |
| US20220204918A1 (en) * | 2019-04-11 | 2022-06-30 | Merck Patent Gmbh | Cell culture media comprising keto acids |
| WO2021008571A1 (zh) * | 2019-07-16 | 2021-01-21 | 信达生物制药(苏州)有限公司 | 高密度连续接种的细胞培养方法及其应用 |
| US20220315887A1 (en) * | 2019-08-01 | 2022-10-06 | Bristol-Myers Squibb Company | Methods of improving protein productivity in fed-batch cell cultures |
| BR112023017717A2 (pt) * | 2021-05-03 | 2024-01-09 | Boehringer Ingelheim Int | Método para produção de espesolimabe |
| WO2023114897A2 (en) | 2021-12-15 | 2023-06-22 | Homology Medicines, Inc. | Methods and compositions for the production of adeno-associated virus |
| EP4490278A1 (en) * | 2022-03-07 | 2025-01-15 | Ultragenyx Pharmaceutical Inc. | Modified batch aav production systems and methods |
| AU2023338683A1 (en) * | 2022-09-06 | 2025-03-13 | Amgen Inc. | Lean perfusion cell culture methods |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ATE439435T1 (de) | 1991-03-01 | 2009-08-15 | Dyax Corp | Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| US5856179A (en) * | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
| AU2002226028A1 (en) | 2000-11-14 | 2002-05-27 | Board Of Regents, Unversity Of Texas Systems | Mutant human factor ix with an increased resistance to inhibition by heparin |
| CA2431230C (en) | 2000-12-20 | 2011-02-22 | Bayer Pharmaceuticals Corporation | A device and method for seed-train expansion of mammalian cells |
| CN1547608A (zh) | 2001-09-04 | 2004-11-17 | Ĭ��ר������˾ | 经修饰的因子ix |
| MXPA04008180A (es) | 2002-02-21 | 2005-05-16 | Tokyo Gas Co Ltd | Reactivo de diagnostico para evaluacion de efecto farmacologico de medicina, y metodo y reactivo para seleccionar agentes farmaceuticos que comprenden enzima, inhibidor de enzima o ligando receptor y/o promedicamentos del mismo para uno que tiene alt |
| EP1587540B1 (en) | 2003-01-09 | 2021-09-15 | MacroGenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
| US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| CN104593277A (zh) * | 2004-03-05 | 2015-05-06 | 帝斯曼知识产权资产管理有限公司 | 用于通过连续灌注和交互切向流来培养细胞的方法 |
| US7294484B2 (en) * | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
| TW200804416A (en) | 2006-06-19 | 2008-01-16 | Nautilus Technology Llc | Modified coagulation factor IX polypeptides and use thereof for treatment |
| EP2500413A1 (en) * | 2006-09-13 | 2012-09-19 | Abbott Laboratories | Cell culture improvements |
| US7700734B2 (en) | 2007-01-09 | 2010-04-20 | Shu-Wha Lin | Recombinant human factor IX and use thereof |
| CN104004739A (zh) | 2007-10-15 | 2014-08-27 | 北卡罗来纳-查佩尔山大学 | 半衰期延长的人因子ix变体 |
| WO2009140015A2 (en) | 2008-04-16 | 2009-11-19 | Bayer Healthcare Llc | Site-directed modification of factor ix |
| AU2009244633A1 (en) | 2008-04-16 | 2009-11-12 | Bayer Healthcare Llc | Modified Factor IX polypeptides and uses thereof |
| EP2444491B1 (en) | 2008-04-21 | 2016-11-16 | Novo Nordisk Healthcare Ag | Hyperglycosylated human coagulation factor IX |
| BRPI0910454A2 (pt) * | 2008-04-23 | 2018-03-27 | Symphogen As | processo para produção de uma proteína policlonal |
| SI2331678T1 (sl) * | 2008-06-13 | 2015-12-31 | Janssen Biotech, Inc. | Postopki za dobivanje visoke gostote viabilnih celic v sesalski celični kulturi |
| MX353233B (es) | 2009-12-06 | 2018-01-08 | Bioverativ Therapeutics Inc | Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos. |
| SG182618A1 (en) * | 2010-01-25 | 2012-08-30 | Ventria Bioscience | Methods & compositions for improving protein production |
| WO2012006635A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Processable single chain molecules and polypeptides made using same |
| CN103140237A (zh) | 2010-07-09 | 2013-06-05 | 比奥根艾迪克依蒙菲利亚公司 | 因子ix多肽及其使用方法 |
| US9611310B2 (en) | 2010-07-09 | 2017-04-04 | Bioverativ Therapeutics Inc. | Systems for factor VIII processing and methods thereof |
| JP5923529B2 (ja) | 2011-03-18 | 2016-05-24 | ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ | 細胞培養用可撓性バッグ |
| HUE033279T2 (en) | 2011-07-01 | 2017-11-28 | Amgen Inc | Mammalian cell culture |
| US20160289633A1 (en) | 2013-12-20 | 2016-10-06 | Biogen Ma Inc. | Use of Perfusion Seed Cultures to Improve Biopharmaceutical Fed-Batch Production Capacity and Product Quality |
-
2014
- 2014-12-19 US US15/038,698 patent/US20160289633A1/en not_active Abandoned
- 2014-12-19 WO PCT/US2014/071701 patent/WO2015095809A1/en not_active Ceased
- 2014-12-19 EP EP14827357.6A patent/EP3083933A1/en active Pending
- 2014-12-19 JP JP2016532136A patent/JP2017500017A/ja not_active Withdrawn
-
2020
- 2020-01-06 JP JP2020000268A patent/JP2020054388A/ja not_active Withdrawn
-
2022
- 2022-12-09 JP JP2022197095A patent/JP2023022317A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017500017A5 (enExample) | ||
| KR101644954B1 (ko) | 배양 동안 락테이트의 축적을 감소시키는 방법 및 폴리펩타이드를 생산하는 방법 | |
| US11912739B2 (en) | Sterile chromatography and manufacturing processes | |
| US12480947B2 (en) | Method for generating high affinity antibodies | |
| KR101591671B1 (ko) | 항체의 이질성을 감소시키는 방법 및 그 항체의 제조방법 | |
| US9908932B2 (en) | Methods of shifting an isoelectric profile of a protein product and uses thereof | |
| SI2904092T1 (en) | Ingredients and procedures for the production of glycoproteins | |
| CN105378071A (zh) | 用于产生稳定转染细胞的方法和组合物 | |
| JP6108170B2 (ja) | 細胞培養用培地 | |
| HRP20250491T1 (hr) | Upotreba monensina za regulaciju glikozilacije rekombinantnih proteina | |
| US20160108357A1 (en) | Methods of culturing a cell | |
| CN104854125A (zh) | 在不存在全能核酸酶的情况下分离synagis*的方法 | |
| KR20200083564A (ko) | 단백질 산물을 제조하는 방법 | |
| Pörtner et al. | Cell culture technology | |
| AU2017393059B2 (en) | Method for producing corneal epithelial cell mass | |
| RU2786078C2 (ru) | Способы стерильной хроматографии и производства | |
| Bodeus et al. | In Vitro Production of Rat Monoclonal Antibodies | |
| CN105051203A (zh) | 三羧酸(tca)中间体用于控制细胞培养中的氨产生的用途 | |
| US11254964B1 (en) | Cell culture methods for increased cell viability | |
| Dewan | Evaluation of Zinc Compounds and LongTM R3 IGF-I as Alternatives for Insulin in Serum-free Media to Support Growth and Productivity of an Sp2/0 Cell Line | |
| CN117126858A (zh) | 一种用于预防和/或治疗肿瘤的抗TGFβ的人源化纳米抗体 | |
| JP5466326B1 (ja) | ラットモノクローナル抗体作製用パートナー細胞およびそのスクリーニング方法 | |
| CN117230078A (zh) | 一种抗TGFβ的人源化纳米抗体及其制备方法和用途 | |
| CN102234641A (zh) | 一种快速获取特异性人源抗体可变区基因序列的方法 | |
| CN112279917A (zh) | 可应用于肿瘤细胞捕获的小鼠抗细胞表面糖蛋白cd138的单克隆抗体 |